Experimental Ebola Drug 'ZMapp' Takes a Step Closer to the Market

by Dr. Trupti Shirole on  September 18, 2015 at 11:21 AM Drug News   - G J E 4
During the recent Ebola outbreak in West Africa, an experimental drug ZMapp was used to treat some of the healthcare workers infected with Ebola, even though the drug had never undergone a full-scale clinical trial. Not all those who were given the drug survived, but some who were cured of Ebola believed that it worked for them.
 Experimental Ebola Drug 'ZMapp' Takes a Step Closer to the Market
Experimental Ebola Drug 'ZMapp' Takes a Step Closer to the Market

A clinical trial of ZMapp is going on in West Africa. The drug has been in the development phase for more than a decade. The US Food and Drug Administration has granted a fast track status to ZMapp, and this could speed its arrival on the market, reported the drug-maker.

Larry Zeitlin, president of LeafBio and Mapp Biopharmaceutical, said, "The decision by the FDA is an important milestone."

Prior to getting the fast-track status, ZMapp had been granted 'orphan drug' designation, which provides financial and other regulatory incentives meant to encourage development.

Kevin Whaley, chief executive officer of LeafBio and Mapp Biopharmaceutical, based in San Diego, California, said, "We are hopeful that this step will accelerate access to ZMapp once safety and efficacy are demonstrated to FDA's satisfaction in ongoing clinical trials."

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like